{
    "2020-10-12": [
        [
            {
                "time": "2020-10-12",
                "original_text": "工业大麻每日谈20201012【天风证券中小市值】",
                "features": {
                    "keywords": [
                        "工业大麻",
                        "天风证券",
                        "中小市值"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "化工"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "天风证券：目前尚未控股恒泰证券",
                "features": {
                    "keywords": [
                        "天风证券",
                        "恒泰证券",
                        "控股"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "金融"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "券商为何密集“补血”？年内定增、配股超千亿",
                "features": {
                    "keywords": [
                        "券商",
                        "补血",
                        "定增",
                        "配股"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "金融"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "新三板督导券商挑选指南——献给所有新三板公司",
                "features": {
                    "keywords": [
                        "新三板",
                        "督导券商",
                        "挑选指南"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "金融",
                        "中小企业"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "券商为何密集“补血”？年内定增、配股超千亿，中小券商突围路径还有哪些？",
                "features": {
                    "keywords": [
                        "券商",
                        "补血",
                        "定增",
                        "配股",
                        "中小券商",
                        "突围路径"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "金融"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}